admin:
annual report in july - this is definite
drawdowns from the $30m - potential, announcement may not be required, could be within the annual report, or happen later than that
trials underway
mss - the promised "summer update" - i'm guessing late august, biomarker updates, hints regarding ORR
trials maybe kicking off
mss rollover - announce that it is starting / has started? - really a total mystery
**********
PR that aren't coming until sept thru end of year, imo
admin
FDA data submission pre-BTD or BTD - october is my guess, will include validated 16 week scan data
another shareholder update - december?
trials underway
mss - post-ESMO PR end of october - this is definite
EAP tnbc - some sort of update possible 4th quarter
Alzheimers - some sort of update possible 4th quarter
trials maybe kicking off
mss 2nd line at city of hope - i'll say could be any time sept 1 thru end of year, could begin dosing in 2026
SPY phase 1 dose finding - i'll say could be any time sept 1 thru end of year, could begin dosing in 2026
other trials - at least one announcement on something else will occur - will begin dosing in 2027
(mss front line, pancreatic, gbm, ?)
(LATCH - a mystery even deeper than the rollover mystery) - no prediction from me
(stroke, other hiv stuff, liver stuff, other stuff - until i hear something new they remain off my radar)